Argenx 113-1902 Study

Brief description of study

The main goal of this study is to look at the long-term safety and effect of a drug called efgartigimod PH20 SC in people with chronic inflammatory demyelinating polyneuropathy (CIDP).The active substance that is being tested is called efgartigimod (ARGX-113), which is co formulated with PH20 for Subcutaneous injection (called efgartigimod PH20 SC).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 13 Mar 2024. Study ID: 844002

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).